Nyfosa AB (publ) (STO:NYF)
Sweden · Delayed Price · Currency is SEK 84.60
-0.50 (-0.59%)
Aug 1, 2025, 5:29 PM CET
Achilles Therapeutics Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Rental Revenue | 3,317 | 3,341 | 3,242 | 2,853 | 2,312 | 2,001 | Upgrade |
Other Revenue | 326 | 328 | 311 | 298 | 147 | 252 | Upgrade |
Total Revenue | 3,643 | 3,669 | 3,553 | 3,151 | 2,459 | 2,253 | Upgrade |
Revenue Growth (YoY | 1.45% | 3.26% | 12.76% | 28.14% | 9.14% | 21.06% | Upgrade |
Property Expenses | 1,093 | 1,129 | 1,109 | 1,060 | 809 | 625 | Upgrade |
Selling, General & Administrative | 202 | 185 | 186 | 161 | 128 | 132 | Upgrade |
Other Operating Expenses | -15 | -15 | -6 | -14 | -5 | 26 | Upgrade |
Total Operating Expenses | 1,280 | 1,299 | 1,289 | 1,207 | 932 | 783 | Upgrade |
Operating Income | 2,363 | 2,370 | 2,264 | 1,944 | 1,527 | 1,470 | Upgrade |
Interest Expense | -1,135 | -1,208 | -1,194 | -614 | -374 | -314 | Upgrade |
Interest & Investment Income | 15 | 15 | 11 | 10 | 1 | 29 | Upgrade |
Income (Loss) on Equity Investments | 180 | 210 | -8 | 672 | 888 | - | Upgrade |
Currency Exchange Gain (Loss) | -2 | -2 | 1 | -1 | -8 | - | Upgrade |
Other Non-Operating Income | -350 | -195 | -384 | 288 | -42 | -37 | Upgrade |
EBT Excluding Unusual Items | 1,071 | 1,190 | 690 | 2,299 | 1,992 | 1,148 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 187 | Upgrade |
Gain (Loss) on Sale of Assets | -49 | -49 | 29 | 225 | -42 | 327 | Upgrade |
Asset Writedown | -583 | -887 | -1,381 | -664 | 1,694 | 737 | Upgrade |
Pretax Income | 332 | 254 | -662 | 1,860 | 3,644 | 2,399 | Upgrade |
Income Tax Expense | 145 | 141 | -22 | 166 | 532 | 174 | Upgrade |
Earnings From Continuing Operations | 187 | 113 | -640 | 1,694 | 3,112 | 2,225 | Upgrade |
Minority Interest in Earnings | 1 | 1 | 1 | -5 | - | - | Upgrade |
Net Income | 188 | 114 | -639 | 1,689 | 3,112 | 2,225 | Upgrade |
Preferred Dividends & Other Adjustments | 47 | 57 | 63 | 43 | 4 | - | Upgrade |
Net Income to Common | 141 | 57 | -702 | 1,646 | 3,108 | 2,225 | Upgrade |
Net Income Growth | - | - | - | -45.73% | 39.87% | 61.00% | Upgrade |
Basic Shares Outstanding | 208 | 202 | 191 | 191 | 188 | 182 | Upgrade |
Diluted Shares Outstanding | 208 | 202 | 191 | 191 | 188 | 182 | Upgrade |
Shares Change (YoY) | 7.75% | 5.60% | 0.01% | 1.60% | 3.30% | 8.33% | Upgrade |
EPS (Basic) | 0.68 | 0.28 | -3.67 | 8.62 | 16.53 | 12.23 | Upgrade |
EPS (Diluted) | 0.67 | 0.28 | -3.67 | 8.61 | 16.49 | 12.23 | Upgrade |
EPS Growth | - | - | - | -47.79% | 34.88% | 48.61% | Upgrade |
Dividend Per Share | 2.800 | 2.800 | - | 4.000 | 3.800 | 3.000 | Upgrade |
Dividend Growth | 100.00% | - | - | 5.26% | 26.67% | - | Upgrade |
Operating Margin | 64.86% | 64.59% | 63.72% | 61.70% | 62.10% | 65.25% | Upgrade |
Profit Margin | 3.87% | 1.55% | -19.76% | 52.24% | 126.39% | 98.76% | Upgrade |
EBITDA | 2,364 | 2,372 | 2,265 | 1,946 | 1,528 | 1,471 | Upgrade |
EBITDA Margin | 64.89% | 64.65% | 63.75% | 61.76% | 62.14% | 65.29% | Upgrade |
D&A For Ebitda | 1 | 2 | 1 | 2 | 1 | 1 | Upgrade |
EBIT | 2,363 | 2,370 | 2,264 | 1,944 | 1,527 | 1,470 | Upgrade |
EBIT Margin | 64.86% | 64.59% | 63.72% | 61.70% | 62.10% | 65.25% | Upgrade |
Effective Tax Rate | 43.68% | 55.51% | - | 8.92% | 14.60% | 7.25% | Upgrade |
Revenue as Reported | 3,644 | 3,670 | 3,553 | 3,151 | 2,459 | 2,035 | Upgrade |
Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.